NYSE:JNJ

Johnson & Johnson Recognized in the U.S. by ENERGY STAR as a “Partner Leader on Climate"

by Paulette Frank, Worldwide Vice President, Environmental Health, Safety & Sustainability at Johnson & Johnson
Blog

On this 50th Anniversary of Earth Day, I am proud to share that J&J is recognized in the U.S. by ENERGY STAR as a “Partner Leader on Climate”. We have had a long-standing commitment to the health of our environment because we understand that environmental health and human health are inextricably linked. we work to reduce our carbon footprint because we recognize that energy reduction and clean energy projects are good for the environment and for human health.

The Road to a Vaccine, Ep. 2: What it Takes to Create a Coronavirus Vaccine in Record Time

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

Each week our host Lisa Ling will talk to leading scientists and researchers, healthcare workers on the front lines and public health experts around the world working collaboratively to bring an end to the deadly pandemic.

Succeeding in Times of Uncertainty

by Meri Stevens, Worldwide Vice President Deliver - Johnson & Johnson Supply Chain
Blog

Everywhere I turn—as the world faces the challenges brought about by the Covid-19 pandemic—there are constant reminders of the disruption surrounding us.

Chairman and CEO Alex Gorsky Profiled by the Financial Times About Johnson & Johnson's Work on a Potential Covid-19 Vaccine

The article explores what guided the decision, which is just the latest example of our Chairman and CEO's people-first approach to leadership at our healthcare company.
Article

Johnson & Johnson scientists are fast at work on a potential vaccine for Covid-19 that our company plans to provide on a not-for-profit basis.

“I’m a Scientist Working on a Potential Covid-19 Vaccine”: Meet a Researcher Who's Studying a Promising Candidate

Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
Blog

Weeks before many people had even heard of the novel coronavirus, Roland Zahn, Ph.D., was already studying the disease—specifically, how it could be stopped.​

The Road to a Vaccine, Ep. 1: How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

Providing Critical Resources to HCPs in Time of Crisis

Blog

Published on March 27, 2020
by Sandra Humbles, Vice President, Global Education Solutions, Johnson & Johnson Medical Devices

Today, the heroic healthcare professionals (HCPs) on the front lines of care in communities around the world need our support more than ever before.

"I Have Never Seen a Moment So Rich in Collaboration, Ingenuity and Acts of Bravery": Johnson & Johnson Announces It Has Identified a Lead Covid-19 Vaccine Candidate

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a Covid-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.
Blog

By Alex Gorsky, Chairman & CEO, 

The Covid-19 pandemic is one of the greatest challenges to our society in living memory.

Yet even as we are heartbroken by the lives lost and the strain on our institutions and communities, countless people have been working tirelessly to offer the world a reason to feel pride, inspiration and hope.

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Summary: 
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020
Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply
Press Release
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020
Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply

What You Need to Know About How Johnson & Johnson's Supply Chain Is Responding to the Covid-19 Pandemic

The company's Chief Global Supply Chain Officer shares the measures the company has taken to maintain its supply chain operations during the current novel coronavirus outbreak.
Article

The effects of the global Covid-19 pandemic are undeniable.

As the world rapidly learns to adapt to an ever-changing landscape, Johnson & Johnson's supply chain, which produces everything from contact lenses to prescription medications to fever reducers, is currently holding steady and meeting patient needs.

Pages

Subscribe to NYSE:JNJ